The financials
IRADIMED CORPORATION by the numbers
IRADIMED CORPORATION (IRMD) reported revenue of $22M in Q1 2026 (quarter ended March 31, 2026), up 13% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $5.8M (26% of revenue). For the full year FY2025, revenue was $84M (+14% year on year) and net income $22M. Its largest region in 2026-Q1 was US at $18M, 82% of the disclosed total, just ahead of Non Us at 18%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $22M | $20M | +13% |
| Gross profit | $17M | $15M | +13% |
| Operating income | $7.2M | $5.4M | +33% |
| Net income | $5.8M | $4.7M | +24% |
| Diluted EPS | $0.45 | $0.37 | +22% |
| Geographic | Revenue | Share |
|---|---|---|
| US | $18M | 82% |
| Non Us | $4.0M | 18% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q1 2026Total $22.0M (+3.7%)
US grew +13% year on yearNon Us +11% year on year
Segment Latestquarter on quarteryear on year
- US$18.0M$18.0MQoQ -0.50%year on year +13%-0.50%+13%
- Non Us$4.0M$4.0MQoQ +28%year on year +11%+28%+11%
- International--QoQ -year on year ---